Skip to main content

Table 1 Demographic and clinical characteristics of patients at baseline

From: Cardiac radiation dose predicts survival in esophageal squamous cell carcinoma treated by definitive concurrent chemotherapy and intensity modulated radiotherapy

Characteristic

No. of patients (%)

Age (years)

 Median (Range)

56 (34–81)

  ≤ 56

61 (50.4)

  >  56

60 (49.6)

Gender

 Male

116 (95.9)

 Female

5 (4.1)

Body mass index (kg/m2)

 Median (Range)

21.3 (15.5–30.0)

  ≤ 21.3

61 (50.4)

  >  21.3

60 (49.6)

Body surface area (m2)

 Median (Range)

1.65 (1.3–2.1)

  ≤ 1.65

63 (52.1)

  >  1.65

58 (47.9)

Eastern Cooperative Oncology Group performance status

 0

11 (9.1)

 1

95 (78.5)

 2

14 (11.6)

 3

1 (0.8)

Stage

 I

2 (1.7)

 II

8 (6.6)

 III

111 (91.7)

Tumor location

 U

51 (42.1)

 M

30 (24.8)

 L

17 (14.0)

 U + M (from U to M)

9 (7.4)

 U + M + L (from U to L)

1 (0.8)

 M + L (from M to L)

13 (10.7)

Smoking

 Yes

109 (90.1)

 No

12 (9.9)

Alcohol

 Yes

111 (91.7)

 No

10 (8.3)

Hypertension

 Yes

24 (19.8)

 No

97 (80.2)

Diabetes

 Yes

15 (12.4)

 No

106 (87.6)

Cardiovascular disease

 Yes

6 (5.0)

 No

115 (95.0)

Heart volume (ml)

  ≤ 592

61 (50.4)

  > 592

60 (49.6)

Chemotherapy regimen

 Fluoropyrimidine-based

113 (93.4)

 Taxane-based

4 (3.3)

 Others

4 (3.3)

Radiation dose (Gy)

 Median (range)

61.2 (50–66.6)

  ≤ 61.2

68 (56.2)

  >  61.2

53 (43.8)

PTV prescribed to 36 Gy (ml)

 Median (Range)

780.4 (97.1–1799.5)

PTV prescribed to 50 Gy (ml)

 Median (Range)

640.0 (26.0–1761.2)

  1. Abbreviations: L Lower thoracic esophagus, M Middle thoracic esophagus, PTV Planning target volume, U Upper thoracic and cervical esophagus